Identification
- Summary
Sorbitol is a product that can be used as a laxative to relieve constipation, and also as a urologic irrigating fluid. May also be used as a pharmaceutical sweetener.
- Brand Names
- Cystosol
- Generic Name
- Sorbitol
- DrugBank Accession Number
- DB01638
- Background
A polyhydric alcohol with about half the sweetness of sucrose. Sorbitol occurs naturally and is also produced synthetically from glucose. It was formerly used as a diuretic and may still be used as a laxative and in irrigating solutions for some surgical procedures.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Sorbitol (DB01638)
- Weight
- Average: 182.1718
Monoisotopic: 182.07903818 - Chemical Formula
- C6H14O6
- Synonyms
- (−)-sorbitol
- D-(−)-sorbitol
- D-glucitol
- D-Sorbit
- D-Sorbitol
- G-ol
- L-Gulitol
- Sorbitol
- External IDs
- 7B5697N
- E 420
- E-420
- E420
- FEMA NO. 3029
- NSC-25944
Pharmacology
- Indication
Used as a non-stimulant laxative via an oral suspension or enema.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Constipation Combination Product in combination with: Docusate (DB11089) ••• ••• •••••••• Used in combination to treat Constipation Combination Product in combination with: Glycerin (DB09462) •••••••••••• Used in combination to treat Constipation Combination Product in combination with: Glycerin (DB09462) •••••••••••• ••••••••• Treatment of Constipation ••• ••• Used in combination to treat Constipation caused by pregnancy Combination Product in combination with: Glycerin (DB09462) •••••••••••• ••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Sorbitol exerts its laxative effect by drawing water into the large intestine, thereby stimulating bowel movements.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Sorbitol will either be excreted in the urine by the kidneys, or metabolized to carbon dioxide and dextrose.
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Acute oral toxicity (LD50): 15900 mg/kg [Rat].
- Pathways
Pathway Category Galactosemia Disease Fructose and Mannose Degradation Metabolic Galactose Metabolism Metabolic Fructosuria Disease Fructose Intolerance, Hereditary Disease - Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Sorbitol which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Sorbitol which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Sorbitol which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Sorbitol which could result in a higher serum level. Acetazolamide The risk or severity of dehydration can be increased when Acetazolamide is combined with Sorbitol. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Sorbitol Irrigant 3.3 g/100mL Irrigation B. Braun Medical Inc. 1978-02-16 Not applicable US 
Sorbitol Irrigant 30.00 g/1000.00mL Irrigation Baxter Healthcare Corporation 1980-05-30 Not applicable US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image GeriCare Sorbitol Solution Liquid 70 mg/100mL Rectal Geri-Care Pharmaceuticals, Corp 2020-01-01 Not applicable US Sorbitol Solution 1 g/1mL Rectal H&H Laboratories, Inc. 2013-06-10 Not applicable US Sorbitol Solution 13.5 g/15mL Rectal Geri-Care Pharmaceuticals, Corp 2000-01-01 2022-05-01 US Sorbitol Solution 258.2 g/474mL Oral Geritrex Llc 2012-07-17 Not applicable US Sorbitol Rougier Pws 5gm Powder, for solution 5 g / pck Oral Rougier Pharma Division Of Ratiopharm Inc 1975-12-31 2001-09-05 Canada 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Char-flo With Sorbitol - Sus Sorbitol (400 mg / mL) + Activated charcoal (208 mg / mL) Suspension Oral Ballard Medical Products 1997-08-20 2004-08-04 Canada CHI. JOA (Anti-inflammatory effect, antibacterial effect, stomatitis improvement, plaque removal) Sorbitol (1 g/100g) + Cinnamon (1 g/100g) + Levomenthol (1 g/100g) + Menthol (1 g/100g) + Myrrh (1 g/100g) + Pear (1 g/100g) + Peppermint (1 g/100g) + Sea salt (47 g/100g) + Silicon dioxide (1 g/100g) + Xylitol (1 g/100g) Powder Topical BIOHERB Co., Ltd. 2023-07-11 2024-07-10 US Cystosol W 3% Hexitols Sorbitol (2.5 g / 100 mL) + Mannitol (500 mg / 100 mL) Liquid Irrigation Baxter Laboratories 1989-12-31 Not applicable Canada Fluad Tetra Sorbitol (1.175 mg) + Citric acid (0.04 mg) + Influenza A virus A/Cambodia/e0826360/2020 IVR-224 (H3N2) antigen (formaldehyde inactivated) (15 μg) + Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (formaldehyde inactivated) (15 μg) + Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated) (15 μg) + Influenza virus type B (Victoria) (15 μg) + Polysorbate 80 (1.175 mg) + Sodium citrate (0.66 mg) + Squalene (9.75 mg) Injection, suspension Intramuscular Seqirus Netherlands B.V. 2022-06-06 Not applicable EU 
Fluad Tetra Sorbitol (1.175 mg) + Citric acid (0.04 mg) + Influenza A virus A/Cambodia/e0826360/2020 IVR-224 (H3N2) antigen (formaldehyde inactivated) (15 μg) + Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (formaldehyde inactivated) (15 μg) + Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated) (15 μg) + Influenza virus type B (Victoria) (15 μg) + Polysorbate 80 (1.175 mg) + Sodium citrate (0.66 mg) + Squalene (9.75 mg) Injection, suspension Intramuscular Seqirus Netherlands B.V. 2022-06-06 Not applicable EU - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image CHI. JOA (Anti-inflammatory effect, antibacterial effect, stomatitis improvement, plaque removal) Sorbitol (1 g/100g) + Cinnamon (1 g/100g) + Levomenthol (1 g/100g) + Menthol (1 g/100g) + Myrrh (1 g/100g) + Pear (1 g/100g) + Peppermint (1 g/100g) + Sea salt (47 g/100g) + Silicon dioxide (1 g/100g) + Xylitol (1 g/100g) Powder Topical BIOHERB Co., Ltd. 2023-07-11 2024-07-10 US
Categories
- ATC Codes
- B05CX02 — Sorbitol
- B05CX — Other irrigating solutions
- B05C — IRRIGATING SOLUTIONS
- B05 — BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
- B — BLOOD AND BLOOD FORMING ORGANS
- A06AD — Osmotically acting laxatives
- A06A — DRUGS FOR CONSTIPATION
- A06 — DRUGS FOR CONSTIPATION
- A — ALIMENTARY TRACT AND METABOLISM
- Drug Categories
- Alcohols
- Alimentary Tract and Metabolism
- Blood and Blood Forming Organs
- Blood Substitutes and Perfusion Solutions
- Carbohydrates
- Compounds used in a research, industrial, or household setting
- Diagnostic Agents
- Diet, Food, and Nutrition
- Drugs for Constipation
- Drugs that are Mainly Renally Excreted
- Enemas
- Flavoring Agents
- Food
- Food Additives
- Food Ingredients
- Gastrointestinal Agents
- Indicators and Reagents
- Irrigating Solutions
- Laboratory Chemicals
- Laxatives
- Osmotic Laxatives
- Physiological Phenomena
- Sugar Alcohols
- Sweetening Agents
- Tests for Bile Duct Patency
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as sugar alcohols. These are hydrogenated forms of carbohydrate in which the carbonyl group (aldehyde or ketone, reducing sugar) has been reduced to a primary or secondary hydroxyl group.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- Sugar alcohols
- Alternative Parents
- Monosaccharides / Secondary alcohols / Polyols / Primary alcohols / Hydrocarbon derivatives
- Substituents
- Alcohol / Aliphatic acyclic compound / Hydrocarbon derivative / Monosaccharide / Polyol / Primary alcohol / Secondary alcohol / Sugar alcohol
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- glucitol (CHEBI:17924)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 506T60A25R
- CAS number
- 50-70-4
- InChI Key
- FBPFZTCFMRRESA-JGWLITMVSA-N
- InChI
- InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4+,5-,6-/m1/s1
- IUPAC Name
- (2R,3R,4R,5S)-hexane-1,2,3,4,5,6-hexol
- SMILES
- OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
References
- Synthesis Reference
Gerhard Darsow, "Process for the preparation of epimer-free sugar alcohols from the group consisting of xylitol, sorbitol (D-glucitol), 4-O-.beta.-D-galactopyranosyl-D-glucitol and 4-O-.alpha.-D-glucopyranosyl-D-sorbitol." U.S. Patent US5162517, issued August, 1985.
US5162517- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000247
- KEGG Drug
- D00096
- KEGG Compound
- C00794
- PubChem Compound
- 5780
- PubChem Substance
- 46507030
- ChemSpider
- 5576
- 9945
- ChEBI
- 17924
- ChEMBL
- CHEMBL1682
- ZINC
- ZINC000018279893
- PharmGKB
- PA451455
- PDBe Ligand
- SOR
- Wikipedia
- Sorbitol
- PDB Entries
- 1d8c / 1fqa / 1fqb / 1xih / 2dxr / 2vft / 2xin / 3brf / 3xim / 4dvo … show 15 more
- MSDS
- Download (47.1 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Other Human Immunodeficiency Virus (HIV) Infections 1 4 Completed Treatment Constipation / Ileus / Surgery 1 3 Active Not Recruiting Treatment Hereditary Motor and Sensory Neuropathies 1 3 Completed Treatment Constipation 1 3 Completed Treatment Hyperkalemia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Suspension Oral Powder Topical Liquid Irrigation Injection, suspension Intramuscular Liquid Rectal 70 mg/100mL Aerosol, spray Oral Solution Intravenous Gel Rectal Enema; liquid Rectal Liquid Rectal Enema Rectal 12.5 % w/w Emulsion Rectal Injection Intravenous 17.5 g/100ml Powder, for solution Oral Powder, for solution Oral 10 G Enema Rectal 0.35 g Aerosol Oral Capsule Oral Enema Rectal Solution Rectal Irrigant Irrigation 3.3 g/100mL Irrigant Irrigation 30.00 g/1000.00mL Solution Oral 258.2 g/474mL Solution Rectal 1 g/1mL Solution Rectal 13.5 g/15mL Solution Irrigation Powder, for solution Oral 5 g / pck Irrigant Urethral Spray Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 111 http://pubchem.ncbi.nlm.nih.gov/compound/5780?from=summary water solubility 2.75E+006 mg/L (at 30 °C) MULLIN,JW (1972) logP -2.20 SANGSTER (1994) logS 1.09 ADME Research, USCD pKa 13.6 BENSON,FR (1978) - Predicted Properties
Property Value Source Water Solubility 229.0 mg/mL ALOGPS logP -2.7 ALOGPS logP -3.7 Chemaxon logS 0.1 ALOGPS pKa (Strongest Acidic) 12.59 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 6 Chemaxon Polar Surface Area 121.38 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 38.4 m3·mol-1 Chemaxon Polarizability 17.12 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.6525 Blood Brain Barrier - 0.5997 Caco-2 permeable - 0.8958 P-glycoprotein substrate Non-substrate 0.662 P-glycoprotein inhibitor I Non-inhibitor 0.9535 P-glycoprotein inhibitor II Non-inhibitor 0.9551 Renal organic cation transporter Non-inhibitor 0.9252 CYP450 2C9 substrate Non-substrate 0.8706 CYP450 2D6 substrate Non-substrate 0.878 CYP450 3A4 substrate Non-substrate 0.7431 CYP450 1A2 substrate Non-inhibitor 0.824 CYP450 2C9 inhibitor Non-inhibitor 0.9419 CYP450 2D6 inhibitor Non-inhibitor 0.9412 CYP450 2C19 inhibitor Non-inhibitor 0.9232 CYP450 3A4 inhibitor Non-inhibitor 0.9402 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.958 Ames test Non AMES toxic 0.9132 Carcinogenicity Non-carcinogens 0.7823 Biodegradation Ready biodegradable 0.8595 Rat acute toxicity 1.1260 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9709 hERG inhibition (predictor II) Non-inhibitor 0.9329
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 140.7072088 predictedDarkChem Lite v0.1.0 [M-H]- 141.4256088 predictedDarkChem Lite v0.1.0 [M-H]- 140.9728088 predictedDarkChem Lite v0.1.0 [M-H]- 140.6596088 predictedDarkChem Lite v0.1.0 [M-H]- 137.9955088 predictedDarkChem Lite v0.1.0 [M-H]- 144.37202 predictedDeepCCS 1.0 (2019) [M+H]+ 141.0578088 predictedDarkChem Lite v0.1.0 [M+H]+ 142.8872088 predictedDarkChem Lite v0.1.0 [M+H]+ 144.5523088 predictedDarkChem Lite v0.1.0 [M+H]+ 141.6874088 predictedDarkChem Lite v0.1.0 [M+H]+ 136.6751088 predictedDarkChem Lite v0.1.0 [M+H]+ 146.76758 predictedDeepCCS 1.0 (2019) [M+Na]+ 140.4480088 predictedDarkChem Lite v0.1.0 [M+Na]+ 142.4560627 predictedDarkChem Standard v0.1.0 [M+Na]+ 141.4674088 predictedDarkChem Lite v0.1.0 [M+Na]+ 140.3301088 predictedDarkChem Lite v0.1.0 [M+Na]+ 137.8301088 predictedDarkChem Lite v0.1.0 [M+Na]+ 152.6801 predictedDeepCCS 1.0 (2019)
Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:55